Gina Keiffer
Internal Medicine · Philadelphia, PANPI 1366885592
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,756 of the $3,223 with a category attached, or 85.5%. Astellas Pharma US Inc accounts for 85.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $2,756 and has fallen 98.8% since, to $32 in 2024.
Across 12 payments — averaging $268.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$3K
- Servier Pharmaceuticals LLC$319
- Jazz Pharmaceuticals Inc.$81
- Genentech, Inc.$67
Across 75 payments — averaging $5561.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$225K
- AbbVie$187K
- Stemline Therapeutics Inc.$5K
What the payments were for
- Consulting fees$2,75686%
- Food & beverage$1485%
- Education$31910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 1 | $2,756 |
| Servier Pharmaceuticals LLC | 8 | $319 |
| Jazz Pharmaceuticals Inc. | 1 | $81 |
| Genentech, Inc. | 2 | $67 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XOSPATA$2,756
How this compares
$3,223 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Philadelphia
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- David GoldmannPhiladelphia$525K
- Eyob FeyssaPhiladelphia$328K
- Emil AbramianPhiladelphia$199K
- Michael KnightPhiladelphia$178K
- James BlakePhiladelphia$164K
- Gina SimonciniPhiladelphia$158K
- James LewisPhiladelphia$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.